These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 27101422)

  • 1. Randomized Open-Label Phase 1 Study of the Pharmacokinetics of Ferric Maltol in Inflammatory Bowel Disease Patients with Iron Deficiency.
    Bokemeyer B; Krummenerl A; Maaser C; Howaldt S; Mroß M; Mallard N
    Eur J Drug Metab Pharmacokinet; 2017 Apr; 42(2):229-238. PubMed ID: 27101422
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ferric maltol is effective in correcting iron deficiency anemia in patients with inflammatory bowel disease: results from a phase-3 clinical trial program.
    Gasche C; Ahmad T; Tulassay Z; Baumgart DC; Bokemeyer B; Büning C; Howaldt S; Stallmach A;
    Inflamm Bowel Dis; 2015 Mar; 21(3):579-88. PubMed ID: 25545376
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ferric maltol therapy for iron deficiency anaemia in patients with inflammatory bowel disease: long-term extension data from a Phase 3 study.
    Schmidt C; Ahmad T; Tulassay Z; Baumgart DC; Bokemeyer B; Howaldt S; Stallmach A; Büning C;
    Aliment Pharmacol Ther; 2016 Aug; 44(3):259-70. PubMed ID: 27237709
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacodynamics and safety of ferric carboxymaltose: a multiple-dose study in patients with iron-deficiency anaemia secondary to a gastrointestinal disorder.
    Geisser P; Rumyantsev V
    Arzneimittelforschung; 2010; 60(6a):373-85. PubMed ID: 20648929
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-Term Effectiveness of Oral Ferric Maltol vs Intravenous Ferric Carboxymaltose for the Treatment of Iron-Deficiency Anemia in Patients With Inflammatory Bowel Disease: A Randomized Controlled Noninferiority Trial.
    Howaldt S; Domènech E; Martinez N; Schmidt C; Bokemeyer B
    Inflamm Bowel Dis; 2022 Mar; 28(3):373-384. PubMed ID: 33988236
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral Ferric Maltol for the Treatment of Iron-Deficiency Anemia in Patients With CKD: A Randomized Trial and Open-Label Extension.
    Pergola PE; Kopyt NP
    Am J Kidney Dis; 2021 Dec; 78(6):846-856.e1. PubMed ID: 34029682
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and Efficacy of Ferric Carboxymaltose in the Treatment of Iron Deficiency Anaemia in Patients with Inflammatory Bowel Disease, in Routine Daily Practice.
    Stein J; Aksan A; Klemm W; Nip K; Weber-Mangal S; Dignass A
    J Crohns Colitis; 2018 Jun; 12(7):826-834. PubMed ID: 29955835
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ferric Maltol: A New Oral Iron Formulation for the Treatment of Iron Deficiency in Adults.
    Khoury A; Pagan KA; Farland MZ
    Ann Pharmacother; 2021 Feb; 55(2):222-229. PubMed ID: 32633548
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ferric maltol Real-world Effectiveness Study in Hospital practice (FRESH): clinical characteristics and outcomes of patients with inflammatory bowel disease receiving ferric maltol for iron-deficiency anaemia in the UK.
    Cummings JF; Fraser A; Stansfield C; Beales I; Sebastian S; Hoque S
    BMJ Open Gastroenterol; 2021 Feb; 8(1):. PubMed ID: 33622683
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical significance of C-reactive protein levels in predicting responsiveness to iron therapy in patients with inflammatory bowel disease and iron deficiency anemia.
    Iqbal T; Stein J; Sharma N; Kulnigg-Dabsch S; Vel S; Gasche C
    Dig Dis Sci; 2015 May; 60(5):1375-81. PubMed ID: 25501922
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pediatric Crohn's disease, iron deficiency anemia and intravenous iron treatment: a follow-up study.
    Valério de Azevedo S; Maltez C; Lopes AI
    Scand J Gastroenterol; 2017 Jan; 52(1):29-33. PubMed ID: 27576956
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of ferric carboxymaltose in correcting iron-deficiency anemia: a review of randomized controlled trials across different indications.
    Bailie GR
    Arzneimittelforschung; 2010; 60(6a):386-98. PubMed ID: 20648930
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics, safety and tolerability of intravenous ferric carboxymaltose: a dose-escalation study in volunteers with mild iron-deficiency anaemia.
    Geisser P; Banké-Bochita J
    Arzneimittelforschung; 2010; 60(6a):362-72. PubMed ID: 20648928
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TREATMENT OF ANEMIA AND IMPROVEMENT OF QUALITY OF LIFE AMONG PATIENTS WITH CROHN'S DISEASE: experience using ferric carboxymaltose.
    Sobrado CW; Cançado RD; Sobrado LF; Frugis MO; Sobrado MF
    Arq Gastroenterol; 2015 Dec; 52(4):255-9. PubMed ID: 26840464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment with Noripurum EV
    Venturieri MO; Komati JTS; Lopes LHC; Sdepanian VL
    Scand J Gastroenterol; 2019 Feb; 54(2):198-204. PubMed ID: 30782036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ferric maltol (ST10): a novel oral iron supplement for the treatment of iron deficiency anemia in inflammatory bowel disease.
    Stallmach A; Büning C
    Expert Opin Pharmacother; 2015; 16(18):2859-67. PubMed ID: 26595432
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FERGIcor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease.
    Evstatiev R; Marteau P; Iqbal T; Khalif IL; Stein J; Bokemeyer B; Chopey IV; Gutzwiller FS; Riopel L; Gasche C;
    Gastroenterology; 2011 Sep; 141(3):846-853.e1-2. PubMed ID: 21699794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anemia and iron deficiency in inflammatory bowel disease: an open, prospective, observational study on diagnosis, treatment with ferric carboxymaltose and quality of life.
    Befrits R; Wikman O; Blomquist L; Hjortswang H; Hammarlund P; Bajor A; Klintman D; Blom H
    Scand J Gastroenterol; 2013 Sep; 48(9):1027-32. PubMed ID: 23889159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of Reticulocyte Hemoglobin Content in the Assessment of Iron Deficiency in Children With Inflammatory Bowel Disease.
    Syed S; Kugathasan S; Kumar A; Prince J; Schoen BT; McCracken C; Ziegler TR; Suchdev PS
    J Pediatr Gastroenterol Nutr; 2017 May; 64(5):713-720. PubMed ID: 27429427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized, open-label, non-inferiority study of intravenous iron isomaltoside 1,000 (Monofer) compared with oral iron for treatment of anemia in IBD (PROCEED).
    Reinisch W; Staun M; Tandon RK; Altorjay I; Thillainayagam AV; Gratzer C; Nijhawan S; Thomsen LL
    Am J Gastroenterol; 2013 Dec; 108(12):1877-88. PubMed ID: 24145678
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.